DAY 1

October 5, 2020 – PART I

Introduction, Keynote Lecture, Session I

00:00:00 – Introductory Notes – Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

00:14:20 – KEYNOTE: Gene Therapy for Neurodegeneration – Ronald Crystal, MD, Weill Cornell Medical College

00:55:14 – Session I: NOVEL APPROACHES FOR NEUROINFLAMMATION – Chair: Lauren Friedman, PhD, Alzheimer’s Drug Discovery Foundation

00:57:21 – Preclinical Development of an Antibody Therapeutic and an Imaging Agent Targeting Fibrin-Mediated Neuroinflammation – Jeffrey Stavenhagen, PhD, TheriniBio

01:13:40 – Phase 1b Study in AD Patients with Neuroinflammation – CJ Barnum, PhD, INmune Bio

01:27:30 – Development of Novel Anti-Neuroinflammatory Small Molecule Drug Candidates – Linda Van Eldik, PhD, University of Kentucky

01:43:25 – Imaging Brain Inflammatory States: Focus on CSF1R – Martin Pomper, MD, PhD, Johns Hopkins University

01:59:12 – SESSION I – PANEL DISCUSSION

October 5, 2020 – PART II

(Sessions 2 and 3)

00:00 – Session II: METABOLIC AND MITOCHONDRIAL APPROACHES FOR ALZHEIMER’S DISEASE – Chair: Meriel Owen, PhD, Alzheimer’s Drug Discovery Foundation

00:01:27 – Benfotiamine in Alzheimer’s Disease: A Pilot Study – Gary Gibson, PhD, Burke Neurological Institute

00:17:15 – Effect of Novel GLP1 Analogue, Liraglutide on Microglial Activation and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease
Paul Edison, MD, PhD, Imperial College London

00:33:40 – SESSION II – PANEL DISCUSSION

00:43:26 – Session III: EMERGING AREAS IN DRUG DEVELOPMENT FOR NEURODEGENERATION – Chair: Nick McKeehan, Alzheimer’s Drug Discovery Foundation

00:45:00 – The Role of Senescent Cells in Alzheimer’s Disease and Dementia – Darren Baker, PhD, MS, Mayo Clinic

01:01:58 – Autophagy in Alzheimer’s Disease and Related Dementias – Ralph Nixon, MD, PhD, NYU Langone Health

01:21:18 – APOE4 Leads to Breakdown in the Blood-brain Barrier Predicting Cognitive Decline – Berislav Zlokovic, MD, PhD, Keck School of Medicine, USC

01:36:50 – Accelerating Therapy Development for Alzheimer’s: from Open Science to Open Drug Discovery – Suzana Petanceska, PhD, NIH/NIA

01:53:30 – SESSION III – PANEL DISCUSSION